172 related articles for article (PubMed ID: 12098604)
1. T cell-mediated immune responses in melanoma: implications for immunotherapy.
Wang RF; Zeng G; Johnston SF; Voo K; Ying H
Crit Rev Oncol Hematol; 2002 Jul; 43(1):1-11. PubMed ID: 12098604
[TBL] [Abstract][Full Text] [Related]
2. Human tumor antigens for cancer vaccine development.
Wang RF; Rosenberg SA
Immunol Rev; 1999 Aug; 170():85-100. PubMed ID: 10566144
[TBL] [Abstract][Full Text] [Related]
3. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
5. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.
Wang RF
Immunol Rev; 2002 Oct; 188():65-80. PubMed ID: 12445282
[TBL] [Abstract][Full Text] [Related]
6. Human tumor antigens: implications for cancer vaccine development.
Wang RF
J Mol Med (Berl); 1999 Sep; 77(9):640-55. PubMed ID: 10569202
[TBL] [Abstract][Full Text] [Related]
7. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
[TBL] [Abstract][Full Text] [Related]
8. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
9. MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design.
Zeng G
J Immunother (1991); 2001 May; 24(3):195-204. PubMed ID: 11395634
[TBL] [Abstract][Full Text] [Related]
10. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.
Wang RF
Trends Immunol; 2001 May; 22(5):269-76. PubMed ID: 11323286
[TBL] [Abstract][Full Text] [Related]
11. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells.
Wang RF
Methods; 2003 Mar; 29(3):227-35. PubMed ID: 12725788
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
13. Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.
Kiniwa Y; Li J; Wang M; Sun C; Lee JE; Wang RF; Wang HY
PLoS One; 2015; 10(5):e0124094. PubMed ID: 25993655
[TBL] [Abstract][Full Text] [Related]
14. T-cell-directed cancer vaccines: the melanoma model.
Wang E; Phan GQ; Marincola FM
Expert Opin Biol Ther; 2001 Mar; 1(2):277-90. PubMed ID: 11727535
[TBL] [Abstract][Full Text] [Related]
15. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines.
Maeurer MJ; Storkus WJ; Kirkwood JM; Lotze MT
Melanoma Res; 1996 Feb; 6(1):11-24. PubMed ID: 8640065
[TBL] [Abstract][Full Text] [Related]
16. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
17. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
18. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
19. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
